Cargando…
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer
Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We performed a CTEP-sponsored Phase II clinical trial of saracatinib in previously treated pancreas cancer patients, with a prim...
Autores principales: | Arcaroli, John, Quackenbush, Kevin, Dasari, Arvind, Powell, Rebecca, McManus, Martine, Tan, Aik-Choon, Foster, Nathan R, Picus, Joel, Wright, John, Nallapareddy, Sujatha, Erlichman, Charles, Hidalgo, Manuel, Messersmith, Wells A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544442/ https://www.ncbi.nlm.nih.gov/pubmed/23342270 http://dx.doi.org/10.1002/cam4.27 |
Ejemplares similares
-
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017) -
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
por: Lang, Liwei, et al.
Publicado: (2018) -
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016) -
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
por: Du, Guifang, et al.
Publicado: (2020) -
An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
por: Danson, Sarah, et al.
Publicado: (2019)